Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase.

Siriwardana G, Bradford A, Coy D, Zeitler P.

Mol Endocrinol. 2006 Sep;20(9):2010-9. Epub 2006 Apr 13.

PMID:
16613992
2.
4.

Growth hormone-releasing hormone stimulates mitogen-activated protein kinase.

Pombo CM, Zalvide J, Gaylinn BD, Diéguez C.

Endocrinology. 2000 Jun;141(6):2113-9.

PMID:
10830298
5.

Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor.

Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A, Kiaris H.

Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5575-9. Epub 2007 Mar 19.

6.

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S.

J Cell Physiol. 2006 May;207(2):420-7.

PMID:
16419029
7.

GHRH proliferative action on somatotrophs is cell-type specific and dependent on Pit-1/GHF-1 expression.

Solloso A, Barreiro L, Seoane R, Nogueira E, Cañibano C, Alvarez CV, Zalvide J, Diéguez C, Pombo CM.

J Cell Physiol. 2008 Apr;215(1):140-50.

PMID:
17941086
8.

Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway.

Yang CM, Chien CS, Hsiao LD, Pan SL, Wang CC, Chiu CT, Lin CC.

Br J Pharmacol. 2001 Apr;132(7):1531-41.

9.

The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.

Pozsgai E, Schally AV, Hocsak E, Zarandi M, Rick F, Bellyei S.

Int J Oncol. 2011 Oct;39(4):1025-32. doi: 10.3892/ijo.2011.1098. Epub 2011 Jun 23.

PMID:
21701777
10.

Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.

Zhao L, Yano T, Osuga Y, Nakagawa S, Oishi H, Wada-Hiraike O, Tang X, Yano N, Kugu K, Schally AV, Taketani Y.

Int J Oncol. 2008 Mar;32(3):593-601.

PMID:
18292936
11.

Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.

Köster F, Engel JB, Schally AV, Hönig A, Schröer A, Seitz S, Hohla F, Ortmann O, Diedrich K, Buchholz S.

Breast Cancer Res Treat. 2009 Jul;116(2):273-9. doi: 10.1007/s10549-008-0120-4. Epub 2008 Jul 16.

PMID:
18629632
12.

Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor.

Barabutis N, Siejka A, Schally AV, Block NL, Cai R, Varga JL.

J Mol Endocrinol. 2010 Feb;44(2):127-34. doi: 10.1677/JME-09-0121. Epub 2009 Nov 6.

PMID:
19897610
13.

Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart.

Granata R, Trovato L, Gallo MP, Destefanis S, Settanni F, Scarlatti F, Brero A, Ramella R, Volante M, Isgaard J, Levi R, Papotti M, Alloatti G, Ghigo E.

Cardiovasc Res. 2009 Jul 15;83(2):303-12. doi: 10.1093/cvr/cvp090. Epub 2009 Mar 17.

14.

Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival.

Florea V, Majid SS, Kanashiro-Takeuchi RM, Cai RZ, Block NL, Schally AV, Hare JM, Rodrigues CO.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17260-5. doi: 10.1073/pnas.1420375111. Epub 2014 Nov 17.

15.

Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers.

Chatzistamou I, Schally AV, Kiaris H, Politi E, Varga J, Kanellis G, Kalofoutis A, Pafiti A, Koutselini H.

Eur J Endocrinol. 2004 Sep;151(3):391-6.

16.

Internalization and trafficking of the human and rat growth hormone-releasing hormone receptor.

Veyrat-Durebex C, Pomerleau L, Langlois D, Gaudreau P.

J Cell Physiol. 2005 May;203(2):335-44.

PMID:
15499571
17.

sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation.

Lahlou H, Saint-Laurent N, Estève JP, Eychène A, Pradayrol L, Pyronnet S, Susini C.

J Biol Chem. 2003 Oct 10;278(41):39356-71. Epub 2003 Jul 22.

Supplemental Content

Support Center